1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on August 17, 2025

Incyte Stock Gets Relative Strength Rating Lift
INCY

Investor's Business Daily

2 months ago

Incyte Stock Gets Relative Strength Rating Lift

Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
INCY

TipRanks

2 months ago

Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
INCY

Investor's Business Daily

2 months ago

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
INCY

Investor's Business Daily

2 months ago

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY

Business Wire

2 months ago

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
INCY

Barchart

2 months ago

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

FDA Extends INCY's Application for Opzelura Label Expansion
INCY

Zacks

2 months ago

FDA Extends INCY's Application for Opzelura Label Expansion

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call
INCY

StockStory

2 months ago

5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
INCY

StockStory

2 months ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

INCY

MT Newswires

2 months ago

Incyte Says FDA Extends Review Period for Ruxolitinib Cream

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
INCY

Business Wire

2 months ago

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
INCY

Insider Monkey

2 months ago

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
INCY

Zacks

2 months ago

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

INCY

MT Newswires

2 months ago

Incyte's Drug to Treat Follicular Lymphoma Receives FDA Approval

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

2 months ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value
INCY

Simply Wall St.

2 months ago

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY

Zacks

2 months ago

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
INCY

TipRanks

2 months ago

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

3 Unpopular Stocks in Hot Water
INCY

StockStory

2 months ago

3 Unpopular Stocks in Hot Water

INCY

MT Newswires

2 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

QGEN Stock Rises in After Market Following Partnership With Incyte
INCY

Zacks

2 months ago

QGEN Stock Rises in After Market Following Partnership With Incyte

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
INCY

Medical Device Network

2 months ago

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms

INCY

MT Newswires

2 months ago

Stifel Upgrades Incyte to Buy From Hold, Adjusts Price Target to $107 From $75

INCY

MT Newswires

2 months ago

Jefferies Adjusts Price Target on Incyte to $82 From $76, Maintains Buy Rating

INCY

MT Newswires

2 months ago

QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers

INCY

MT Newswires

2 months ago

Incyte Says 86% of Blood Cancer Patients Responsive to Higher Doses of Drug Candidate

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
INCY

Insider Monkey

2 months ago

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
INCY

Business Wire

2 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY

Business Wire

2 months ago

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Specialised Therapeutics announces expanded partnership with Incyte
INCY

TipRanks

2 months ago

Specialised Therapeutics announces expanded partnership with Incyte

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY

Business Wire

2 months ago

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
INCY

Zacks

2 months ago

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
INCY

Zacks

2 months ago

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

US High Growth Tech Stocks To Watch In June 2025
INCY

Simply Wall St.

2 months ago

US High Growth Tech Stocks To Watch In June 2025

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
INCY

Business Wire

2 months ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
INCY

Zacks

3 months ago

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

3 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

3 months ago

Truist Securities Adjusts Price Target on Incyte to $73 From $72, Maintains Hold Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead
INCY

StockStory

3 months ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Mid-Cap Stocks with Questionable Fundamentals
INCY

StockStory

3 months ago

3 Mid-Cap Stocks with Questionable Fundamentals

FDA approves Incyte’s retifanlimab combo for SCAC treatment
INCY

Pharmaceutical Technology

3 months ago

FDA approves Incyte’s retifanlimab combo for SCAC treatment

Incyte Gets FDA Approval for Zynyz in New Cancer Indication
INCY

Zacks

3 months ago

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

INCY

MT Newswires

3 months ago

Leerink Partners Adjusts Incyte Price Target to $96 From $95

INCY

MT Newswires

3 months ago

Incyte Says FDA Approves Zynyz for Anal Cancer Treatment

INCY

MT Newswires

3 months ago

Argus Lowers Price Target on Incyte to $75 From $80

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY

Business Wire

3 months ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

INCY

Argus Research

3 months ago

Analyst Report: Incyte Corp.

INCY

Argus Research

3 months ago

Market Update: CSCO, FCX, INCY, XRX, SMCI

INCY

MT Newswires

3 months ago

Incyte to Pay Novartis $280 Million to Resolve Jakafi Royalties Dispute

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
INCY

Insider Monkey

3 months ago

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
INCY

StockStory

3 months ago

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

3 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What To Expect From Natera’s (NTRA) Q1 Earnings
INCY

StockStory

3 months ago

What To Expect From Natera’s (NTRA) Q1 Earnings

INCY

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Syndax Pharmaceuticals Inc Earnings Call

INCY

MT Newswires

3 months ago

Mizuho Adjusts Price Target on Incyte to $70 From $77, Maintains Neutral Rating

High Growth Tech Stocks in US with Strong Potential for Investors
INCY

Simply Wall St.

4 months ago

High Growth Tech Stocks in US with Strong Potential for Investors

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

4 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

4 months ago

Leerink Partners Raises Price Target on Incyte to $95 From $92

INCY

MT Newswires

4 months ago

Stifel Lowers Price Target on Incyte to $75 From $77

INCY

MT Newswires

4 months ago

TD Cowen Lowers Price Target on Incyte to $86 From $88

INCY

MT Newswires

4 months ago

Morgan Stanley Adjusts Incyte's Price Target to $68 From $65

INCY

MT Newswires

4 months ago

RBC Raises Price Target on Incyte to $67 From $64, Keeps Sector Perform Rating

Incyte First Quarter 2025 Earnings: Beats Expectations
INCY

Simply Wall St.

4 months ago

Incyte First Quarter 2025 Earnings: Beats Expectations

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
INCY

GuruFocus.com

4 months ago

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

INCY

Morningstar Research

4 months ago

Analyst Report: Incyte Corporation

INCY

MT Newswires

4 months ago

Wells Fargo Hikes Price Target on Incyte to $59 From $58

INCY

MT Newswires

4 months ago

Jefferies Adjusts Incyte Price Target to $76 From $75

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
INCY

Zacks

4 months ago

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
INCY

Zacks

4 months ago

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings

3 Value Stocks Facing Headwinds
INCY

StockStory

4 months ago

3 Value Stocks Facing Headwinds

Incyte (INCY) Q1 Earnings and Revenues Top Estimates
INCY

Zacks

4 months ago

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

INCY

MT Newswires

4 months ago

Incyte Q1 Adjusted Earnings, Revenue Rise

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
INCY

StockStory

4 months ago

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY

Associated Press Finance

4 months ago

Incyte: Q1 Earnings Snapshot

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY

Business Wire

4 months ago

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Q1 Earnings Report Preview: What To Look For
INCY

StockStory

4 months ago

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
INCY

Zacks

4 months ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
INCY

Business Wire

4 months ago

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
INCY

Zacks

4 months ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

3 Cash-Heavy Stocks Skating on Thin Ice
INCY

StockStory

4 months ago

3 Cash-Heavy Stocks Skating on Thin Ice

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY

Business Wire

4 months ago

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY

Zacks

4 months ago

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
INCY

Zacks

4 months ago

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

INCY

MT Newswires

4 months ago

JPMorgan Adjusts Incyte Price Target to $68 From $70, Maintains Neutral Rating

INCY

MT Newswires

4 months ago

BofA Adjusts Price Target on Incyte to $87 From $86, Keeps Buy Rating

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
INCY

StockStory

4 months ago

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

INCY

MT Newswires

4 months ago

Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says

Incyte to Report First Quarter Financial Results
INCY

Business Wire

4 months ago

Incyte to Report First Quarter Financial Results

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

4 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
INCY

StockStory

4 months ago

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
INCY

Zacks

4 months ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Exploring 3 High Growth Tech Stocks In The US Market
INCY

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In The US Market

INCY

MT Newswires

4 months ago

RBC Lowers Price Target on Incyte to $64 From $68, Keeps Sector Perform Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead
INCY

StockStory

5 months ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
INCY

GlobeNewswire

5 months ago

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

INCY

MT Newswires

5 months ago

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating

Why Incyte Stock Was Tanking This Week
INCY

Motley Fool

5 months ago

Why Incyte Stock Was Tanking This Week

1 Healthcare Stock on Our Watchlist and 2 to Brush Off
INCY

StockStory

5 months ago

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

Share on Social Networks: